183 related articles for article (PubMed ID: 21735097)
41. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
42. Multisite-directed inhibitors of protein kinase CK2: new challenges.
Świder R; Masłyk M; Martín-Santamaría S; Ramos A; de Pascual-Teresa B
Mol Cell Biochem; 2011 Oct; 356(1-2):117-9. PubMed ID: 21750979
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and biological evaluation of 3-(substituted-benzylidene)-1,3-dihydro-indolin derivatives as human protein kinase CK2 and p60(c-Src) tyrosine kinase inhibitors.
Olgen S; Götz C; Jose J
Biol Pharm Bull; 2007 Apr; 30(4):715-8. PubMed ID: 17409508
[TBL] [Abstract][Full Text] [Related]
44. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
45. Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors.
Hammad S; Bouaziz-Terrachet S; Meghnem R; Meziane D
J Mol Model; 2020 May; 26(6):160. PubMed ID: 32472293
[TBL] [Abstract][Full Text] [Related]
46. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
47. Discovery of novel CK2 leads by cross-docking based virtual screening.
Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
[TBL] [Abstract][Full Text] [Related]
48. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and biological evaluation of 2,6-di(furan-3-yl)anthracene-9, 10-dione as an inhibitor of human protein kinase CK2.
Haidar S; Meyers A; Bollacke A; Jose J
Pharmazie; 2015 Dec; 70(12):772-6. PubMed ID: 26817273
[TBL] [Abstract][Full Text] [Related]
50. The halogenation of natural flavonoids, baicalein and chrysin, enhances their affinity to human protein kinase CK2.
Marzec E; Świtalska M; Winiewska-Szajewska M; Wójcik J; Wietrzyk J; Maciejewska AM; Poznański J; Mieczkowski A
IUBMB Life; 2020 Jun; 72(6):1250-1261. PubMed ID: 32364671
[TBL] [Abstract][Full Text] [Related]
51. Rational Design of Coumarin Derivatives as CK2 Inhibitors by Improving the Interaction with the Hinge Region.
Zhang N; Chen WJ; Zhou Y; Zhao H; Zhong RG
Mol Inform; 2016 Jan; 35(1):15-8. PubMed ID: 27491649
[TBL] [Abstract][Full Text] [Related]
52. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
Gingipalli L; Block MH; Bao L; Cooke E; Dakin LA; Denz CR; Ferguson AD; Johannes JW; Larsen NA; Lyne PD; Pontz TW; Wang T; Wu X; Wu A; Zhang HJ; Zheng X; Dowling JE; Lamb ML
Bioorg Med Chem Lett; 2018 May; 28(8):1336-1341. PubMed ID: 29559278
[TBL] [Abstract][Full Text] [Related]
53. Identification of protein kinase CK2 inhibitors using solvent dipole ordering virtual screening.
Nakanishi I; Murata K; Nagata N; Kurono M; Kinoshita T; Yasue M; Miyazaki T; Takei Y; Nakamura S; Sakurai A; Iwamoto N; Nishiwaki K; Nakaniwa T; Sekiguchi Y; Hirasawa A; Tsujimoto G; Kitaura K
Eur J Med Chem; 2015; 96():396-404. PubMed ID: 25912672
[TBL] [Abstract][Full Text] [Related]
54. Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors.
Ohno H; Minamiguchi D; Nakamura S; Shu K; Okazaki S; Honda M; Misu R; Moriwaki H; Nakanishi S; Oishi S; Kinoshita T; Nakanishi I; Fujii N
Bioorg Med Chem; 2016 Mar; 24(5):1136-41. PubMed ID: 26850376
[TBL] [Abstract][Full Text] [Related]
55. N-substituted Indole-2 and 3-carboxamide derivatives as inhibitors of human protein kinase CK2: in vitro assay and molecular modelling study.
Olgen S; Gratz A; Kurt ZK; Jose J
Acta Chim Slov; 2013; 60(3):628-35. PubMed ID: 24169717
[TBL] [Abstract][Full Text] [Related]
56. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.
Hung MS; Xu Z; Lin YC; Mao JH; Yang CT; Chang PJ; Jablons DM; You L
BMC Cancer; 2009 May; 9():135. PubMed ID: 19419583
[TBL] [Abstract][Full Text] [Related]
57. Thiazole- and selenazole-comprising high-affinity inhibitors possess bright microsecond-scale photoluminescence in complex with protein kinase CK2.
Vahter J; Viht K; Uri A; Manoharan GB; Enkvist E
Bioorg Med Chem; 2018 Oct; 26(18):5062-5068. PubMed ID: 30217463
[TBL] [Abstract][Full Text] [Related]
58. Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?
Bortolato A; Cozza G; Moro S
Anticancer Agents Med Chem; 2008 Oct; 8(7):798-806. PubMed ID: 18855581
[TBL] [Abstract][Full Text] [Related]
59. Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach.
Borgo C; Cesaro L; Hirota T; Kuwata K; D'Amore C; Ruppert T; Blatnik R; Salvi M; Pinna LA
Eur J Med Chem; 2021 Mar; 214():113217. PubMed ID: 33548633
[TBL] [Abstract][Full Text] [Related]
60. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.
Bestgen B; Krimm I; Kufareva I; Kamal AAM; Seetoh WG; Abell C; Hartmann RW; Abagyan R; Cochet C; Le Borgne M; Engel M; Lomberget T
J Med Chem; 2019 Feb; 62(4):1803-1816. PubMed ID: 30689953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
